Sign In
Media & Investors
Skip Navigation LinksSanten > EMEA > Media & Investors > News > Santen enters into a strategic cooperation with OFF Italia to offer new treatment options to its customers across EMEA

Contact
Santen Pharmaceutical welcomes your inquiries and opinions.

Santen enters into a strategic cooperation with OFF Italia to offer new treatment options to its customers across EMEA

11/15/2018

OFF Italia S.r.l and Santen SA, the European subsidiary of Santen Pharmaceutical Co. Ltd., entered into a licence and supply agreement with the objective to extend the offering of OFF Italia’s ophthalmic innovations to more than 30 countries across EMEA.

 

According to the terms of the agreement, OFF Italia, an Italian company established in 2014 by senior executives within ophthalmology, has granted to Santen, a global organisation dedicated to the field of ophthalmology for over 125 years, the rights to commercialise five products from its eye care portfolio.

 

The rights include the possibility to co-develop new products or build upon existing product lines to respond flexibly to patient and physician needs. The focus of this collaboration will be to identify new therapeutic solutions and innovative formulations with solid therapeutic efficacy and tolerability. This will enable the improvement of outcomes within the following areas:

  • retinal pathologies

  • ocular surface disorders

  • eye care

  • glaucoma

  • ophthalmic surgery

“We are very pleased to enter into this strategic collaboration with OFF Italia as we wish to complement our prescription medicines with selected over-the-counter treatment options, especially within Santen’s dry eye disease portfolio,” said Luís Iglesias, President and Head of Santen EMEA. “OFF Italia’s scientific and customer-orientated approach in the development of improved or new treatment options is compelling. These are values that Santen shares to a great extent with OFF Italia, aiming to serve our customers’ needs.”

 

“OFF Italia was searching for a partner to commercialize its own innovative therapeutic solutions in Europe and beyond, entering in a strategic R&D collaboration with a major player in the ophthalmic area. We are delighted to announce the partnership with Santen,” reveals Alessando Zanini, CEO, OFF Italia.

 

Santen-OFF-Italy.jpg

- ENDS -

For more information contact:

OFF Italia srl

Fulvio Foschini

fulvio.foschini@quinthealth.com

+39 338 5099207

 

Santen SA

Siân Boisseau

sian.boisseau@santen.com

+44 7710 022804

Notes to editors

About Santen

As a specialised company dedicated to the ophthalmic field, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products and devices. Santen has long been the market leader in Japan for prescription ophthalmic pharmaceuticals and is now a leader in the sector in the EMEA (Europe, Middle East and Africa) region. With scientific knowledge and organisational capabilities nurtured over nearly 130 years, Santen products and services now reach over 60 countries, contributing to the well-being of patients, their loved ones and consequently to society. For more information, please visit Santen websites www.santen.com (Japan headquarters) and www.santen.eu (EMEA).

 

About OFF Italia

OFF Italia is specialized company in the ophthalmic field. OFF Italia carries out research, development, marketing and sales of ophthalmic products in the ophthalmology field.

 

OFF Italia is a young Italian company founded on the initiative of a group of professionals with more than 30 years’ experience in the ophthalmic area.

 

As a specialized company OFF Italia is focused on the main eye disease areas of as dry eye, cornea, retina, care and para-surgical devices, with clear goals to develop unique and innovative solutions for the improvement of the quality of life of the patients.

 

For more information, please visit OFF Italia website: www.offitalia.it

 

 

 

Date of preparation: November 2018. NP-No product-EMEA-0014